UK markets closed

Amgen Inc. (0R0T.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
243.76-3.37 (-1.36%)
At close: 07:01PM BST
Full screen
Previous close247.13
Bid0.00 x 0
Ask0.00 x 0
Day's range245.74 - 246.69
52-week range211.96 - 296.58
Avg. volume24,951
Market capN/A
Beta (5Y monthly)0.60
PE ratio (TTM)0.24
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Yahoo Finance Video

    The 30-stock secret: ‘Don’t fight Papa Dow’

    JC Parets, founder and chief strategist at All Star Charts, explains why fighting the Dow Breadth is futile and how embracing the approach can simplify your market analysis significantly.   He spoke with Yahoo Finance’s Jared Blikre and Sydnee Fried on "Stocks in Translation." Listen to the full episode here, or wherever you get your podcasts. This post was written by Jared Blikre

  • Yahoo Finance Video

    Nvidia, advances in cancer research, climate change under Trump: Market Domination

    Nvidia (NVDA) continues to dominate the tech sector as the company's shares move past $1,100. The chip giant earned a boost from Elon Musk, who announced that xAI's supercomputer will run on Nvidia technology. Meanwhile, Tesla (TSLA) shareholders are awaiting an important vote on June 13, which will dictate the fate of Musk's proposed pay package of $56 billion. The American Society of Clinical Oncology (ASCO) will hold its annual meeting in Chicago this week, exploring the latest advancements in the cancer research sector. Tom Steyer, Galvanize Climate Solutions Co-Executive Chair, also joins the show to give insight into the state of climate change mitigation under a possible second Trump presidency. For more expert insight and the latest market action, click here.

  • Yahoo Finance Video

    Tapping into the GLP-1 hype? Consider these pharma stocks.

    Enthusiasm for GLP-1 drugs on Wall Street persists, with Eli Lilly (LLY) committing more than $5.3 billion to expand a plant involved in the production of tirzepatide weight-loss and diabetes injections. Jefferies Biotechnology Managing Director Michael Yee joins Market Domination to explain which biotech companies are hidden gems in the GLP-1 craze on Wall Street. "We have said Amgen (AMGN) is one of the most important large-cap companies that we have been very bullish on. And they, too, will go to phase three with a monthly GLP-1. And we think the data is going to be great the end of the year. There's also smaller companies, like Scholar Rock, SRRK, or Corbis that also have new modalities that are interesting," Yee tells Yahoo Finance. For more on the biotech sector and the upcoming annual conference for The American Society of Clinical Oncology, watch the full interview with Michael Yee here:  For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Nicholas Jacobino